Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Definitive agreement to sell Microfluidics business to ARCHIMED, materially reshaping Standard BioTools’ portfolio.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Definitive agreement to sell Microfluidics business to ARCHIMED, materially reshaping Standard BioTools’ portfolio
- Closing expected in approximately 30 days, subject to customary conditions
- Transaction could generate proceeds and reduce operating complexity, but financial terms are not included in the filing
- Completion remains uncertain, with termination fees, competing bids and unmet conditions identified as key risks
Item EX-99.1 · Exhibit EX-99.1
- Definitive agreement to sell Microfluidics business to ARCHIMED, advancing Standard BioTools’ strategic portfolio reshaping
- Expected closing in approximately 30 days, subject to customary conditions
- Microfluidics remains within Standard BioTools until closing, delaying operational and financial separation
- No sale price or transaction proceeds disclosed, limiting near-term valuation assessment
- Completion risks include unmet conditions, termination, expenses, or competing acquisition proposals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.